People · Operator
Named in public records as an officer, director or promoter · active 2015–2021 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Antios Therapeutics Inc. | — | Pharmaceuticals | Series C | $126.4M | $1.7B | 2018 |
| Antiva Biosciences, Inc. | — | Biotechnology | Series B | $96.8M | $457.3M | 2021 |
| Vascular Pharmaceuticals, Inc. | — | Biotechnology | Series B | $47.3M | $119.1M | 2015 |
Benjamin Rovinski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Benjamin Rovinski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wende Hutton | 1 | 16 |
| David Kabakoff | 1 | 7 |
| Craig Gordon | 1 | 6 |
| Richard Shea | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| Richard Kent | 1 | 5 |
| Michael Cannon | 1 | 4 |
| NICOLE VITULLO | 1 | 4 |
| Vinzenz Ploerer | 1 | 4 |
| Michael J Sullivan | 1 | 4 |
| Ken Williams | 1 | 3 |
| Steven P. James | 1 | 3 |
| Jenny Yip | 1 | 3 |
| Vaughn Kailian | 1 | 3 |
| Steven James | 1 | 3 |
| Iyona Rajkomar | 1 | 3 |
| Michael D. Cannon | 1 | 2 |
| GAIL MADERIS | 1 | 2 |
| Wende S. Hutton | 1 | 2 |
| David P. Kabakoff | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.